CardioSert

Company Overview

Snapshot

Founded in March 2012 by Avrahan Shkalim and Noam Peleg, CardioSert operates with 1–10 employees. The company was acquired by Microbot Medical in May 2018, following two funding rounds from three investors, including Magna Capital Partners and Medvest.

Business overview

CardioSert develops advanced tools for interventional cardiologists, focusing on percutaneous coronary intervention (PCI) procedures. Its core products include a proprietary guide wire for navigating complex lesions like chronic total occlusion (CTO) and a pressure guide wire for fractional flow reserve (FFR) measurements. These technologies are designed to enhance safety and efficiency in arterial blockage treatment and assessment, serving the medical devices and cardiology sectors within the global healthcare market.

Strategic signal

In May 2018, Microbot Medical completed its acquisition of novel technology from CardioSert. This acquisition provided Microbot Medical with CardioSert's innovative technology, including R&D information, technical know-how, and intellectual property, signaling a strategic consolidation in the medical device market and validating CardioSert's specialized tools for interventional cardiology.

Company Intelligence Q&A

What is CardioSert's primary focus?

CardioSert develops advanced tools specifically for interventional cardiologists to use during percutaneous coronary intervention (PCI) procedures.

When was CardioSert acquired?

CardioSert was acquired by Microbot Medical in May 2018.

What technology did Microbot Medical acquire from CardioSert?

Microbot Medical acquired CardioSert's novel patent-protected technology, including its innovative CTO tool and FFR tool, along with R&D information, technical know-how, and intellectual property.

Which investors participated in CardioSert's July 2014 funding round?

In July 2014, CardioSert received funding from Magna Capital Partners and Medvest.